Pharmacology & Therapeutics Submission Guide: What to Know Before You Pitch

Even once the invitation issue is resolved, the journal is selective in a very specific way.

Editors are usually asking:

• does the review center on pharmacology, drug actions, or drug targets rather than broad disease biology
• is the manuscript critical and authoritative rather than descriptive
• does the topic matter enough to justify a top-tier pharmacology review slot
• is the review written for readers who want interpretation and direction, not a catalog of papers

That is why even strong review concepts can be the wrong shape here. Pharmacology & Therapeutics is not rewarding comprehensiveness alone. It wants a review that sharpens how the field thinks.

The invitation barrier makes this even more important. If you do have a route into the journal, the manuscript still has to behave like a high-authority pharmacology review from the first page.

Pressure-test these questions first:

• do you actually have an invitation path or prior editorial contact
• is the core narrative about pharmacology rather than general disease mechanism
• can the review make a critical argument about therapies, targets, or drug action
• would the article still sound like pharmacology if the disease context were changed
• is the author team credible enough to carry an authoritative review

If the answer to the first question is no, the practical next move is usually to retarget the idea rather than push ahead with a full draft.

The journal's current public information is unusually clear.

The practical implication is simple: Pharmacology & Therapeutics is less a general submission target than an invitation-gated destination.

That does not mean the journal is irrelevant for authors. It means the useful question is whether your review idea belongs in this editorial class and, if so, whether you have a realistic route in. If not, a nearby review journal is usually the smarter commercial and publication decision.

Failure pattern 1: Treating it like a normal review journal

The most basic failure is procedural. Authors draft a review and only later notice that the journal publishes invited reviews only.

Failure pattern 2: Writing disease biology instead of pharmacology

The journal explicitly allows disease pathophysiology only when it serves a narrative around drug actions or targets. Many reviews fail that test.

Failure pattern 3: Summary without critical judgment

This journal wants authoritative synthesis. A long literature tour without real evaluation usually feels too soft.

Before you invest heavily, a review-journal targeting check can tell you whether the concept belongs in a more realistic outlet.

Failure pattern 4: Assuming a cold proposal email will reopen the door. Authors sometimes treat a speculative outreach note like a substitute for an invitation, but the journal's public guidance points the other way.

For most authors, the strongest strategy is not "submit now." It is one of these:

• determine whether you have an invitation route through editorial contact or prior discussion
• reposition the same topic for a journal that accepts review proposals or unsolicited reviews
• narrow the concept into a more thesis-driven review or commentary for a different owner journal

That is the practical value of a Pharmacology & Therapeutics submission guide. It helps you stop wasting time on a route that is not really open.

If you do have an invitation path, the manuscript should still be built around a few specific elements:

• a drug-action or target-centered narrative
• clear critical evaluation of the field
• authoritative selection rather than encyclopedic coverage
• a forward-looking section on unresolved pharmacology questions

In our pre-submission review work with manuscripts that authors hope might fit Pharmacology & Therapeutics, three patterns show up repeatedly.

• The author discovers too late that the journal is invitation-gated. That alone can save a lot of unnecessary drafting time.
• The review is excellent science but not centered enough on pharmacology. We often see strong disease reviews that belong in a disease or translational medicine journal, not here.
• The article is broad but not authoritative enough in judgment. The topic may be good, but the draft is still summarizing rather than leading.
• The package never explains the invitation route or editorial logic clearly. Even a strong topic can look unrealistic if the cover note does not make the access path and pharmacology case explicit.

A pharmacology review-fit check is useful here because the biggest risk is often owner-journal mismatch, not quality.